The venture capital fund will finance companies in Europe who are in the early stages of development with the goal of advancing them to regulatory approval and commercialization.
The facility in Bloomington, Indiana, belonged to contract drugmaker Catalent. FDA inspectors found issues including a "pest" on the manufacturing line. Novo is buying Catalent to boost Wegovy production. Also: A report says FDA oversight of foreign firms making U.S. market drugs is weak.
Scion Life Sciences Launches with Oversubscribed $310 Million Fund to Create and Build Exceptional Biotech Companies streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Ex-Apple Tree investors launch new $310M life science fund fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.